DrStockPick.com Stocks to Watch!
For Tuesday June 1st, 2010
__
NTRO, NITRO Petroleum Inc., NTRO.OB
NTRO is an energy company engaged in the acquisition and development of oil and natural gas properties in the United States and Canada.
NTRO’s objective is to seek out opportunities in the energy sector that represent low risk opportunities with significant upside, both independently and with joint venture partners.
** NTRO recently reported that it has received a reserve calculation of oil and natural gas estimated for the Big Horn project in the State of Montana.
The reservoir engineering firm of Ramsey Property Management LLC of Oklahoma City were contracted by NTRO to evaluate the potential petroleum reserves.
Ramsey has reported the following initial calculation indicators: 93,900 barrels of high gravity crude oil, 236,000,000 cubic feet of natural gas.
NTRO maintains a 25% working interest in a 1600 acre lease. Drilling regulations provide for a possible ten well drilling program on this lease.
Furthermore, the latest news about NTRO appears to be on a positive note. And investors may be responding to it.
NTRO is in the process of reworking many older wells that are in areas where oil is known to exist.
NTRO’s stock could become a valuable play.
More about NTRO at www.nitropetroleuminc.com.
**************************************************************
PWRM, Power 3 Medical Products Inc., PWRM.OB
PWRM is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease).
PWRM applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, PWRM has developed a portfolio of products including BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro, a serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases, currently engaged in Phase II clinical trials.
These products are designed to analyze proteins and their mutations to assess an individual’s risk for developing disease later in life, a patient’s likelihood of responding to a particular drug, a patient’s risk of disease progression and disease recurrence, to measure a patient’s exposure to drug therapy, to ensure optimal dosing and reduced drug toxicity.
** PWRM, in collaboration with Lourdes R. Bosquez, MD, it has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer – NYSE: PFE), Exelon (Rivastigmine, Novartis – NYSE: NVS), and Namenda (Memantine HCl, Forest Laboratories – NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene.
With these results, PWRM’s NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.
PWRM has filed for patent protection for these findings (one on Alzheimer’s disease specific differential diagnosis in the clinical setting and the other on important differences in pathophysiology and therapeutic options for the genetically distinct groups of Alzheimer’s disease patients) and will be publishing these seminal results in the near future in one of the world’s most prestigious peer-reviewed scientific journals.
Lourdes R. Bosquez, MD, has a large private practice as well as 3 Medical Directorships in Psychiatry. Her current work in the last 9 years has been in dementia at: Cy Fair Medical Hospital, Tomball Texas; Methodist Hospital Willowbrook, Texas; and Directions of Recovery, a substance abuse program. She is a consultant to several large drug companies. Some of her research work includes “Diagnosing Depression in Cancer Children.” She presents papers at a many national neurological meetings.
More about PWRM at www.power3medical.com.
**************************************************************
SSHO, South Shore Resources Inc., SSHO.PK
SSHO is engaged in the manufacturing, marketing, sales and distribution of products which are committed to fuel savings with the use of Hydrogen Generating Modules and related accessories to the transportation and automotive manufacturing industries which are either in development and/or commercialization stages.
SSHO is now poised to commercialize its HyProStar Hydrogen Generator Hybrid Conversion Kit and bring it to the global market. With over 750 million automobiles currently using combustible engines world wide and the increased pressure to reduce greenhouse gases. SSHO is confident that now is the time to aggressively enter this market.
SSHO’s HyProStar system can be installed on any vehicle, regardless of make or model.
As you’ve just read, the market opportunity for SSHO’s product is HUGE!
SSHO’s revenue and earning streams could be dramatically impacted in a positive way.
Keep a close eye on SSHO from now on
**************************************************************
CRWE, Crown Equity Holdings, Inc., CRWE.OB
* CRWE recently reported its financial information for the quarter ending March 31, 2010 **
CRWE’s revenue for the quarter ending March 31, 2010 totaled $324,776 compared to $6,144 during the quarter ending March 31, 2009 representing a +5,186% increase!
CRWE incurred an operating loss of ($8,563) for the quarter ending March 31, 2010 compared to an operating loss for the same period in 2009 of ($255,550). The results included a net loss for the March 31, 2010 quarter of ($127,046) compared to a net loss of ($254,997) during the same period in 2009. The loss in 2010 was due primarily to an unrealized loss of $134,025 on securities held by the Company.
More about CRWE at www.crownequityholdings.com.
**************************************************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more) . Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc. has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB). Crown Equity Holdings, Inc. (CRWE.OB) has received fifty thousand dollars from a third party (Fassi SA) for thirty days of advertisement services for South Shore Resources Inc. (SSHO.PK). Crown Equity Holdings, Inc. (CRWE.OB) has received fifteen thousand dollars in cash from a third party for 15 days of media advertisement services for Nitro Petroleum, Inc. (NTRO.OB).
